Why Big Money Is Loading Up on This Healthcare Compounder

A depressed valuation, steady institutional buying, and unusual options flow all point to the same mid-cap healthcare name.

Twin Turbo Watchlist (Sponsored)

10 “Twin Turbo” Stocks Built for the Next Bull Run

Our analysts just went through every sector, chart, and earnings trend to find the 10 stocks most likely to dominate the rest of this year - and they compiled them all in the Top 10 Best Stocks to Own in the Second Half of 2026.

In this free report, you’ll discover companies primed for a Fed-fueled rally - from AI powerhouses to dividend machines.

These names are already attracting billions in institutional inflows, so this is your chance to position early.

Get the Top 10 Best Stocks to Own in the Second Half of 2026 now - before it’s gone for good.

(By clicking the link above, you agree to receive emails from MarketBeat. You can opt out at any time. - Privacy Policy)

The Cooper Companies, Inc.

August 26 – Pre‑market
Ticker: COO | Sector: Healthcare (Medical Instruments) | Market Cap: $14.17B

30‑Second Take

Why now? Cooper is a healthcare compounder with two sticky businesses: contact lenses and fertility products. Not exciting, but that is the point.

COO has been under pressure most of the year, and a few things have lined up at once for you. GuruFocus's valuation model has it trading roughly 27% below fair value. Ten of the 16 tracked institutional holders added to positions last quarter.

Add unusual call flow on the options desks, and the question becomes whether that valuation gap is enough to pull you in.

This is a defensive medical name with steady cash flow going on sale at a discount that does not usually stick around once the setup gets spotted. Fiscal Q3 earnings are two weeks out.

Trade Setup

Time frame: Swing to medium-term (6-12 weeks)

Edge type: Valuation dislocation plus institutional accumulation

Watch Moves Earlier (Sponsored)

The Market Moves Fast. Stay Ready

Nobody wants to show up after the move has already happened.

If you’re relying on headlines, social media, or late commentary to decide what to watch, you may already be behind.

Sign up for Street Fox stock alerts and get market updates by email. On the next page, you can also add your cell number for intraday SMS alerts.

Don’t try to guess the perfect moment.

Be ready when it happens.

(By clicking the link above, you agree to receive emails from StreetFox. You can opt out at any time. - Privacy Policy)

Poll: You find a stock that's down 60% from its high. The business is still profitable. What's your first move?

Figure out whether the drop reflects reality or overreaction — I read the last 3 earnings transcripts before touching it

Buy a starter position now and plan to add if it drops further

Pass. A stock down 60% is telling you something. I don't fight tape.

Build a short thesis first. If I can't make the bear case convincingly, then I'll consider the bull side.

Snapshot Table

Metric	Value	Current Stance
Price	$73	Bottom third of the 52-week range
52‑week range	$59 - $90	Closer to the low than the high
Market Cap	$14.17B	Mid-cap medical device
P/E Ratio	61.7 trailing, 15.4 forward	GAAP earnings are depressed by charges, so the forward multiple is the honest read
Beta	0.82	Less volatile than the market
Avg Daily Volume	2.6M	Liquid enough for any retail size
Next Catalyst	Fiscal Q3 earnings, Wednesday, September 9, 4:15 PM ET	Two weeks out

Chart

1-Month Synopsis: COO has clawed back roughly 4% over the past month after a brutal stretch earlier in the year, but it still sits in the bottom third of its 52-week range.

The medical device sector took a beating on GLP-1 demand fears and general risk-off pressure in healthcare, and Cooper got dragged along with it.

The interesting part is what is happening beneath the surface. Buying volume picked up on down days, which is usually the fingerprint of institutions accumulating into weakness rather than getting out.

Bull Case

Core thesis: Cooper runs two businesses, both boring in the best way. CooperVision sells contact lenses to a global user base that renews on autopilot. CooperSurgical serves the fertility and women's health market, one of the few reliably growing corners of med-tech you will find.

Neither segment is going to blow up on you. Neither reprices violently on macro noise.

Catalysts: The valuation gap is what makes this interesting. GuruFocus's fair value model shows COO trading roughly 27% below intrinsic value.

You do not often see a healthcare compounder with a beta under 1 on sale like that. And the market's reason for the discount, mostly GLP-1 spillover fear and generic med-device weakness, does not really touch the actual demand picture for contact lenses or fertility products.

Institutional accumulation is the tell. Ten of the 16 major guru funds tracked by GuruFocus added to their COO positions in the most recent filing period. Only three trimmed. When you see that ratio alongside rising call volume in the options market, something is usually cooking.

Big holders do not add on the way down without a thesis.

The near-term catalyst is fiscal Q3 earnings on September 9. Cooper has a habit of guiding conservatively and then delivering. If the print confirms that contact lens demand held up and fertility kept growing, you get multiple expansion off a depressed base.

That is where your return comes from.

Longer term, the fertility market itself is a structural tailwind. Delayed parenthood, IVF adoption, and better insurance coverage all point in one direction. Cooper's positioning there is underappreciated on the sell side.

Bear Case

The GLP-1 overhang is real, even if it is overstated for Cooper specifically. If the market decides weight-loss drugs are reshaping every corner of healthcare demand, defensive med-device names can stay cheap longer than you would like.

Your position could be dead money for a quarter or two.

Earnings risk cuts both ways. If Cooper misses on either segment, or guides fiscal Q4 below the Street, you will see another leg down.

The bar is not high, but medical device disappointments get punished hard right now, and a miss could take the stock back toward its 52-week low.

The company also has FX exposure through its international lens business. Dollar strength has been eating into reported results, with no sign of that easing. That is a headwind you cannot hedge away.

And honestly, the medical device sector remains out of favor. Sector rotation into these defensive corners has not happened yet. You are betting on being early, and being early can look wrong for weeks before it looks smart.

Quick Checklist

✅ Thesis still valid after the latest close
✅ Volume confirms accumulation on weakness
✅ Catalyst date double-checked (fiscal Q3 earnings, September 9, 2026)

Deep‑Dive Links

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha

Everyday Alpha is a publication of Elite Trade Media LLC.

Disclosure: Content is for informational and entertainment purposes only and is not investment advice. Do not base investment decisions on this newsletter. Securities mentioned may be owned by our owners or operators, which could affect our objectivity. Consult a licensed financial advisor before making any investment decision. We may receive compensation from advertisers and affiliate links in this email, including for featured third-party offers.

Everyday Alpha and its parent company are not registered investment advisors, broker-dealers, or financial planners. Nothing published by Everyday Alpha — including but not limited to newsletters, emails, text messages, social media posts, or website content — constitutes personalized investment advice, a recommendation to buy or sell any security, or an offer or solicitation to purchase or sell any financial instrument.

All content is provided strictly for informational and educational purposes. You should not rely on any content published by Everyday Alpha as a substitute for professional financial, legal, or tax advice tailored to your individual circumstances. Always consult a qualified, licensed financial advisor before making any investment decision.

Forward-Looking Statements: Content may contain forward-looking statements, including projections, opinions, and expectations regarding future events or financial performance. These statements are based on current information and assumptions at the time of writing and are inherently uncertain. Actual results may differ materially. Everyday Alpha is under no obligation to update or revise any forward-looking statement after publication.

No Guarantee of Accuracy: While Everyday Alpha strives for accuracy, we make no representation or warranty — express or implied — regarding the completeness, reliability, or timeliness of any information provided. Errors, omissions, and outdated information may occur. All content is provided "as is" without warranty of any kind.

Past Performance: Any reference to past performance of a security, strategy, or index is not indicative of future results. All investments carry risk, including the potential loss of principal. You could lose some or all of your invested capital.

Editorial Process Disclosure: Everyday Alpha uses proprietary research tools, including AI, in its editorial process. All content is reviewed and approved by our editorial team before publication. Readers should independently verify any information before making financial decisions.

Advertising & Affiliate Disclosure: Everyday Alpha receives compensation from third-party advertisers and may include paid promotions, sponsored content, and affiliate links within its publications. When you click on certain links or sign up for third-party services featured in our content, we may receive a commission or flat fee. This compensation may influence which companies or products are covered and how they are presented, though it does not affect our editorial opinions. Sponsored content is provided by advertisers and does not represent the views of Everyday Alpha.

Conflicts of Interest: Contributors, editors, and affiliates of Everyday Alpha may hold positions in securities discussed in our content. These positions may be established or liquidated at any time without notice to readers.

Limitation of Liability: Under no circumstances shall Everyday Alpha, its owners, employees, affiliates, or contributors be liable for any direct, indirect, incidental, consequential, or punitive damages arising from your use of or reliance on any content published by Everyday Alpha.

By reading, subscribing to, or otherwise engaging with Everyday Alpha content, you acknowledge and agree to the terms above.

This email was sent via the beehiiv platform on behalf of Elite Trade Media LLC.

Update your email preferences or unsubscribe here

1032 E Brandon Blvd #9644
Brandon, FL 33511, United States

Sponsored Links